METHOD OF BIOMARKER DETECTION IN COMPANION ANIMALS

    公开(公告)号:US20230096313A1

    公开(公告)日:2023-03-30

    申请号:US17945709

    申请日:2022-09-15

    发明人: Yu-Shan Wang

    摘要: Two methods for quantifying fibrin/fibrinogen degradation products (“FDP”) in a blood sample. The first method features obtaining a blood sample from a non-human animal, centrifuging the blood sample to obtain a first supernatant and collecting the first supernatant, centrifuging the first supernatant to obtain a second supernatant and collecting the second supernatant, diluting the second supernatant, contacting the diluted second supernatant with a reagent that contains antibodies specifically binding to FDP, and detecting an amount of antibodies specifically bound to FDP, thereby quantifying FDP in the blood sample. The second method requires subjecting the diluted second supernatant to a quantitative immunoassay that specifically detects FDP to quantify the amount of FDP in the non-human blood sample.

    SYSTEM AND METHOD FOR A BIOMIMETIC FLUID PROCESSING

    公开(公告)号:US20230009208A1

    公开(公告)日:2023-01-12

    申请号:US17848523

    申请日:2022-06-24

    摘要: A system and method are provided for harvesting target biological substances. The system includes a substrate and a first and second channel formed in the substrate. The channels longitudinally extending substantially parallel to each other. A series of gaps extend from the first channel to the second channel to create a fluid communication path passing between a series of columns with the columns being longitudinally separated by a predetermined separation distance. The system also includes a first source configured to selectively introduce into the first channel a first biological composition at a first channel flow rate and a second source configured to selectively introduce into the second channel a second biological composition at a second channel flow rate. The sources are configured to create a differential between the first and second channel flow rates to generate physiological shear rates along the second channel that are bounded within a predetermined range.

    Methods of diagnosing malignant diseases

    公开(公告)号:US11519914B2

    公开(公告)日:2022-12-06

    申请号:US16480342

    申请日:2018-01-25

    发明人: Esther Rabizadeh

    IPC分类号: G01N33/86 G01N33/574

    摘要: A method for diagnosing a malignant proliferative disease or disorder in a subject, and/or for following up, monitoring or prognosticating the therapy of a malignant proliferative disease or disorder in a subject is disclosed. The method is based on measurement of platelet-mediated fibrinogen-like protein 2 (FGL2) activity in a sample essentially comprising platelets obtained from the subject. In accordance with the disclosed method, platelet-mediated FGL2 activity level higher than control is indicative of the presence of a malignant proliferative disease or disorder in a subject.

    COAGULATION ASSAY APPARATUS AND METHODS THEREOF

    公开(公告)号:US20220373566A1

    公开(公告)日:2022-11-24

    申请号:US17767143

    申请日:2019-10-17

    IPC分类号: G01N33/86 G01N15/06

    摘要: This invention relates to a method and apparatus for determining the activity of coagulation factors in dilute capillary whole blood, citrated whole blood and citrated plasma. It also includes the detection of the hemoglobin amount in a whole blood sample so a correction of the clotting time can be performed thereby making the clotting time values independent of hemoglobin and hematocrit effect.

    APTT PROLONGATION FACTOR ESTIMATION SYSTEM

    公开(公告)号:US20220373565A1

    公开(公告)日:2022-11-24

    申请号:US17620436

    申请日:2020-06-19

    IPC分类号: G01N33/86 G16H10/40

    摘要: An APTT prolongation factor estimation system includes one or more facilities each including an analyzer which measures a blood coagulation reaction of a subject blood specimen, a database which stores data on a blood coagulation reaction and APTT prolongation factor of blood specimens, and a computer which estimates an APTT prolongation factor of the subject blood specimen based on the data on the blood coagulation reaction from the analyzer and the data stored in the database. The facilities each further includes a data transmission unit which transmits, to the computer, the data on the blood coagulation reaction of the subject blood specimen obtained by the analyzer, and a data reception unit which receives a result of the estimation of the APTT prolongation factor, which is obtained by the computer, regarding the subject blood specimen measured by each of the analyzers.

    DETERMINATION OF INTERFERENTS IN A SAMPLE

    公开(公告)号:US20220243250A1

    公开(公告)日:2022-08-04

    申请号:US17720577

    申请日:2022-04-14

    摘要: A method for determining a non-anticoagulant interferent in a blood-derived sample of a subject, the method comprising a) determining a value of a coagulation time-related parameter in the sample; b) comparing the value of the coagulation time-related parameter determined in a) to a value of the coagulation time-related parameter determined in at least one reference sample; and c) based on the result of comparison step b), determining the non-anticoagulant interferent in a blood-derived sample of a subject. A method for identifying a blood-derived sample having insufficient quality is further disclosed, the method comprising determining non-anticoagulant interferent(s) according to the aforesaid method.

    Blood factor monitoring assay and uses thereof

    公开(公告)号:US11372008B2

    公开(公告)日:2022-06-28

    申请号:US15979349

    申请日:2018-05-14

    发明人: Jurg Sommer

    IPC分类号: G01N33/86 G01N33/92 A61K38/48

    摘要: The present disclosure provides methods and compositions for diagnosing and treating subject having a bleeding disorder. The disclosed methods comprise contacting a sample, e.g., a blood or plasma sample obtained from the patient, with an activation mixture comprising an activated coagulation factor and a phospholipid mixture, wherein the activation mixture is dried onto a solid substrate. Also provided is a global hemostasis test based on the integration of clotting time (Ct) and pharmacokinetics data. The methods and compositions presented can be applied to point-of-care diagnostic systems.